Abstract
Aim: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. Patients and Methods: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. Results: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor–positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.

This publication has 38 references indexed in Scilit: